Polypid Ltd

NASDAQ:PYPD   3:59:41 PM EDT
9.75
-0.75 (-7.14%)
Earnings Announcements

Polypid Ltd Provides Corporate Update And Reports Third Quarter 2020 Financial Results

Published: 11/11/2020 11:37 GMT
(PYPD) - Polypid Ltd.
Provides Corporate Update and Reports Third Quarter 2020 Financial Results.
Polypid Ltd - Over 50% of Planned 60 Centers for Ongoing Phase 3 Shield I Trial of D-plex in Abdominal Surgery Have Received Irb Approval.
Polypid Ltd - Phase 3 Shield Ii Trial Advanced; Preparations Underway to Initiate by Year-end 2020.
Polypid Ltd - Evaluating Eu Commercial Partnership Opportunities for D-plex(100).
Polypid Ltd - Qtrly Loss per Share $0.35.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.51

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.51

More details on our Analysts Page.